ReViral Drug Discovery for Respiratory Syncytial Virus (RSV)
  • ReViral is a UK-based biotechnology company with a portfolio of drugs to treat RSV infection
  • The most advanced programme, RV521, is a highly potent fusion inhibitor
  • RV521 has received top-line safety and pharmacokinetic data for Phase 1 single and multiple ascending dose (SAD and MAD) trials
  • RV521 is delivered by a convenient oral dose
  • RV521 is now in Phase 2a trial to provide clinical POC
RV521 best-in-class drug to treat RSV infections
  • RV521 is an orally available antiviral with excellent drug-like characteristics
  • Binds to the RSV fusion protein, blocking viral entry and preventing cell-to-cell spread
  • The compound demonstrates potent activity against multiple clinical strains of RSV

RSV Medical Need

  • RSV is the main cause of hospitalisation for children under the age of 5 and a major cause of hospitalisation for the elderly
  • Currently, there are no effective treatments or vaccines available against RSV
  • There is a clear unmet need for a safe and effective treatment with a simple route of administration
Meet the team...
Latest News
ReViral present at OneNucleus

Reviral's Chief Operating Officer, Rachel Harland, will be delivering a presentation at Chesterford Research Park on the 15th of November as part of the OneNucleus Leadership...

ReViral at Pharma Integrates 2017

ReViral’s CEO, Eddy Littler, will be a panellist at Pharma Integrates 2017 (Biotech CEO Panel Series: Crossing the Valley of Death Between Discovery and Proof of...

ReViral present Phase 2a update at BIO-Europe

ReViral’s CEO, Eddy Littler, will be presenting an update on their Phase 2a clinical proof of concept study for Respiratory Syncytial Virus on Tuesday November 7th at...

Contact us...